1. Crisaborole for the Treatment of Atopic Dermatitis in Indian Patients: An Evidence-Based Consensus Statement.
- Author
-
Godse, Kiran, De, Abhiesh, Sharma, Nidhi, Rajagopalan, Murlidhar, Shah, Bela, Girdhar, Mukesh, Zawar, Vijay, Shankar, Kupra, Godse, Gauri, and Patil, Anant
- Subjects
- *
DERMATOLOGY , *ATOPIC dermatitis , *CULTURAL pluralism , *AGE groups , *QUALITY of life - Abstract
Atopic dermatitis is a chronic inflammatory dermatological condition associated with intense pruritus seen in all age groups and ethnic diversities. It can have a significant impact on the quality of life. The options for treatment include skincare, topical therapies, systemic therapies, and phototherapy. Treatment of atopic dermatitis may be associated with several challenges including suboptimal efficacy, risk of adverse events, and limited patient satisfaction. A better understanding of the pathophysiology of atopic dermatitis has resulted in the evaluation of many treatment options. Phosphodiesterase 4 plays a role in the pathogenesis of atopic dermatitis and hence can be a target for treatment. Crisaborole 2% ointment is a phosphodiesterase 4 enzyme inhibitor approved for the treatment of mild-to-moderate atopic dermatitis in patients above 2 years of age by the USFDA. Currently, it is not approved for use in Indian patients. In this article, the role and potential place of crisaborole in the management of atopic dermatitis in Indian patients based on global experience and evidence is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF